How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World

In a continuing conversation, Bill Andriopoulos, PhD, Head of Global Medical Affairs at Galderma, highlighted global real-world evidence for Dysport (abobotulinumtoxinA) and outlined broader trends shaping the future of aesthetic injectables.

At TOXINS 2026 in Madrid, Spain, Galderma presented pooled postmarketing data from 4 international studies involving more than 1,000 patients across Europe, the US, and Asia treated with Dysport for glabellar lines. The analyses focused on patient-reported outcomes following 1 or more treatment cycles. Across regions, the vast majority of patients reported satisfaction with aesthetic results at 1 month. Patients frequently described outcomes as natural-looking, and many reported feeling more attractive, rested, or refreshed post-treatment. High proportions indicated willingness to undergo repeat treatment and to recommend therapy to others.

According to Andriopoulos, these findings reflect a shift in aesthetic medicine across all regions, where patient satisfaction and experiential factors complement traditional efficacy endpoints. Neuromodulator treatments, he noted, are increasingly integrated into broader self-care practices, reinforcing the value of structured patient-reported outcome measures in routine practice.

“Broadly, we're moving beyond the question ‘does it work?’ to a much more holistic understanding of patient experience and satisfaction. Efficacy is foundational, of course, but how patients feel about their results is just as important,” Andriopoulos said.

Looking ahead, Galderma identifies continued innovation in neuromodulators as a key focus, including expanded access to Relfydess, its ready-to-use liquid neuromodulator. Beyond toxins, Andriopoulos emphasized a growing role for tailored injectable strategies addressing different life stages and skin concerns, including menopause-associated changes and early aging prevention. Hyaluronic acid fillers are increasingly used not only for contouring but also for skin quality and hydration, including off-face areas such as the décolletage. Regenerative approaches are also gaining traction; the company’s biostimulator poly-L-lactic acid (Sculptra) has received European certification for body indications, reflecting momentum toward comprehensive face and body rejuvenation.

A major emerging theme is skin quality as a central treatment objective. Andriopoulos noted that patient perceptions of skin texture, tone, and overall health significantly influence confidence and well-being. However, standardized frameworks to guide these discussions remain limited. Galderma has been collaborating with clinicians and patients to develop practical assessment tools to better characterize skin quality concerns and support long-term treatment planning.